Rezidivierende Harnwegsinfektionen
Anina Hilfiker(University of Basel), Philip Tarr(University of Basel), Martina Germann(Merck KGaA, Darmstadt (Germany)), Anne Meynard(University of Geneva), Waltraud Remmele(St. Claraspital), Karoline Aebi‐Popp(University Hospital of Bern), Marianne Mattmller(Paracelsus Medizinische Privatuniversität), Peter Christiaan Carp, Barbara Hasse(University Hospital of Zurich), Tanja Grandinetti, Lukas Schb, Annette Lehmann, Patricia Spieler, Angela Huttner(University Hospital of Geneva), Saskia Weisskopf, Olivia Altwegg, Gisela Etter
Cited by 0
Related Papers
Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum
|Antimicrobial Resistance and Infection Control|2013|454
How to use biomarkers of infection or sepsis at the bedside: guide to clinicians
|Intensive Care Medicine|2023|293
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
|The Lancet Infectious Diseases|2015|278
Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usage
|Clinical Microbiology and Infection|2019|263
Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials
|Journal of Antimicrobial Chemotherapy|2015|262